Ipsos Healthcare Launches 'NASH' Therapy Monitor

Ipsos Healthcare has launched its Nonalcoholic Steatohepatitis (NASH) Therapy Monitor in the US and EU5 - France, Germany, Italy, Spain, and UK - with other markets available on demand.

The firm says the introduction of its new syndicated study is in response to the growing focus on NASH - a liver disease characterised by rising prevalence, low diagnosis levels and a lack of therapies currently approved for treatment. Part of Ipsos' Global Therapy Monitor Portfolio, the new NASH patient chart audit will enable subscribers to understand and track the treatment of NASH as a number of new drugs arrive on the market.

Ipsos will tap in to knowledge from its Virology & Liver Diseases Centre of Excellence and its Global Therapy Monitors, to answer questions about the disease. Dr Sabina Heinz (pictured), who heads up the NASH Therapy Monitor, comments: 'Given its rising prevalence, low diagnosis levels and lack of approved therapies, NASH is a growing priority for the healthcare industry - and, potentially, a multi-billion-dollar market. The NASH Therapy Monitor will give us deeper insight into the current patient populations and barriers to diagnosis, as well as providing input into forecasts on the potential uptake of new therapies once launched.'

Web site: www.ipsos.com .